“Authorized” Generics Fight Moves To Capitol Hill, FTC
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.
You may also be interested in...
FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say
Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.
FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say
Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.
Congress, Not Court, Is Place To Change "Authorized" Generic Policy, Judge Says
Congress is a better venue for changing FDA's regulation of "authorized" or brand generics, a D.C. Circuit Court of Appeals judge suggests. Teva faces skepticism during oral arguments in its challenge of the agency's refusal to block authorized generics during an ANDA first-filer's 180-day exclusivity.